Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Zonagen (zona) - good buy? -- Ignore unavailable to you. Want to Upgrade?

To: Brander who wrote (2897)	3/21/1998 1:19:00 PM
From: Hank	Read Replies (1) \| Respond to of 7041

Brad, You may be correct concerning Zoloft, CNS is not my area of expertise and I was refering to an old data base. A more recent synopsis of clinical data concerning these drugs can found at www.rxlist.com and the numbers for headache etc. are in fact listed to be much higher than what I originally posted. At any rate, this entire discussion obscures the basic fact that the FDA needs to be convinced that a drug has tangible benefits to offer a patient before it gets approved. Otherwise, the FDA would not have a legitimate reason to reject ANY drug application if it showed even the most marginable degree of efficacy. The fact remains that Vasomax has not been conclusively shown to have a significant degree of efficacy and until SGP backs an NDA in the US, I will continue to believe this. Even then, I will be very skeptical about the outcome of such an application. Rather than nit pick over CNS drug clinical trials, which is not the focus of this thread, it would more constructive if you could explain to me why you think Vasomax will or will not be approved in the US. Hank